Tianjin Tianyao Pharmaceuticals (600488.SH) subsidiary has obtained the drug registration certificate for Tranexamic Acid and Sodium Chloride Injection.

Tianjin Tianyao Pharmaceuticals (600488.SH) announced that its subsidiary Hubei Tianjin Tianyao Pharmaceuticals Co., Ltd. has recently received the "Drug Registration Certificate" for tranexamic acid sodium chloride injection issued by the National Medical Products Administration. Tranexamic acid sodium chloride injection is primarily used for various types of bleeding caused by acute or chronic, localized or systemic primary fibrinolysis. In November 2024, Hubei Tianyao submitted a domestic production drug registration application for this medication to the Drug Evaluation Center of the National Medical Products Administration, which was accepted. In August 2026, it obtained the drug registration certificate issued by the National Medical Products Administration. To date, Hubei Tianyao has invested approximately 3.6 million yuan in the research and development of the tranexamic acid sodium chloride injection project.